Menarini Stemline company information, Employees & Contact Information

Tempus AI and Stemline partner to bridge critical gap in breast cancer care FirstWord Pharma

Insilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M deal Fierce Biotech

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform HIT Consultant

Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU™ (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Business Wire

The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia Wiley Online Library

Matthijs Van Meerveld: New Journey Brings New Responsibilities at Menarini Stemline in New York City Oncodaily

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology EurekAlert!

Stemline Therapeutics’ breast cancer treatment approved Labiotech.eu

Menarini Group to buy Stemline Therapeutics in deal valued at $677m Pharmaceutical Technology

What You Must Know About Stemline Therapeutics, Inc.'s (NASDAQ:STML) Beta Value Yahoo Finance

Italy’s Menarini Group Snaps Up Stemline Therapeutics for $667 Million BioSpace

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare PR Newswire

Italy’s Menarini Group to acquire Stemline Therapeutics for $677M MedCity News

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 Business Wire

Menarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidate Fierce Biotech

FDA approves Stemline's oral SERD for ESR1-mutated breast cancer FirstWord Pharma

Stemline licenses RET inhibitor from U.K. cancer group Fierce Biotech

Menarini to purchase Stemline for up to $677 million, gaining rights to Elzonris FirstWord Pharma

Menarini shows Big Pharma how it's done with first approval for oral SERD drug in breast cancer Fierce Pharma

Stemline admits it learned of—but did not disclose—patient death in cancer trial before $45M stock offering Fierce Biotech

FDA Approves ELZONRIS™ (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy PR Newswire

Stemline first to market with oral SERD for breast cancer pharmaphorum

Stemline Therapeutics expands oncology pipeline The Pharma Letter

HAS Rejects Early Access for Stemline Orserdu in Advanced Breast Cancer, Citing Availability of Suitable Alternatives NAVLIN DAILY

Elzonris Infusion Approved for Aggressive, Rare Blood Disease Medical Professionals Reference

Why Stemline Therapeutics Inc Stock Is Climbing Today The Motley Fool

Stemline Therapeutics: Down, But Not Out citybuzz -

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation PR Newswire Canada

Menarini Group Completes Acquisition of Stemline Therapeutics Via TT